[{"orgOrder":0,"company":"Avenue Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenue Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Avenue Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenue Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Avenue Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenue Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Celecoxib","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"10","companyTruncated":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Celecoxib","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kowa Pharmaceuticals America \/ Undisclosed"},{"orgOrder":0,"company":"YooYoung Pharmaceutical Co., Ltd","sponsor":"CliPS","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"YooYoung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YooYoung Pharmaceutical Co., Ltd \/ CliPS","highestDevelopmentStatusID":"8","companyTruncated":"YooYoung Pharmaceutical Co., Ltd \/ CliPS"},{"orgOrder":0,"company":"YUNGJIN PHARM. CO. LTD","sponsor":"Chonbuk National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"YUNGJIN PHARM. CO. LTD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YUNGJIN PHARM. CO. LTD \/ Chonbuk National University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"YUNGJIN PHARM. CO. LTD \/ Chonbuk National University Hospital"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Grunenthal"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Esteve Quimica","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Esteve Quimica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esteve Quimica \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"Esteve Quimica \/ Premier Research Group"},{"orgOrder":0,"company":"Universit\u00e9 de Montr\u00e9al","sponsor":"Labopharm | MDS Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Universit\u00e9 de Montr\u00e9al","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Universit\u00e9 de Montr\u00e9al \/ Labopharm | MDS Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Universit\u00e9 de Montr\u00e9al \/ Labopharm | MDS Pharma Services"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal \/ Grunenthal"},{"orgOrder":0,"company":"Unither Pharmaceuticals","sponsor":"International Pharmaceutical Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Unither Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Unither Pharmaceuticals \/ International Pharmaceutical Research Center","highestDevelopmentStatusID":"6","companyTruncated":"Unither Pharmaceuticals \/ International Pharmaceutical Research Center"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenue Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenue Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenue Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenue Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenue Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenue Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenue Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenue Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenue Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Athena Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Athena Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Athena Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Bausch Health | Cipher Pharms Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Bausch Health | Cipher Pharms Inc","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Bausch Health | Cipher Pharms Inc"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Bausch Health | Cipher Pharms Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Bausch Health | Cipher Pharms Inc","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Bausch Health | Cipher Pharms Inc"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for (+)-Tramadol Hydrochloride
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
